Transcatheter Valve Delivery Systems Patents: Leaders & Trends 2026
Transcatheter Valve Delivery Systems: Patents, Leading Filers and Where Claim Space Is Still Open
Concentrated at the top. The five leading assignees hold 592 of 1,851 records in scope (32.0%), and the leading ten hold 918 (49.6%) — roughly half the field sits with ten companies. Annual filings climbed to a peak of 136 in 2019, then eased. The tracked decline from 64 filings in 2021 to 32 in 2024 (-50%) covers the last span where the data can be treated as reasonably complete; 2025 and 2026 figures are still filling in as publications catch up to filing dates.
- 1COOK MEDICAL TECHNOLOGIES LLC172
- 2ULTHERA INC121
- 3ROUTE 92 MEDICAL INC111
- 4NEOVASC TIARA INC108
- 5BOARD OF RGT THE UNIV OF TEXAS SYST80
See the full transcatheter valve delivery systems analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in transcatheter valve delivery systems?
Within this dataset of 1,851 records, one assignee leads with 172 records, well ahead of the fifth-place company at 80 and tenth-place company at 58. The top five assignees combined hold 592 records, or 32.0% of all records in scope, and the top ten hold 918, or 49.6%. That leaves roughly half the field distributed across a long tail of smaller filers, so a single leader does not equate to full control of the space.
Is patent filing in this space growing or slowing down?
Filing activity peaked at 136 records in 2019 and has since declined, with a tracked drop from 64 filings in 2021 to 32 in 2024, a fall of 50% over that span. 2024 is the most recent year in this dataset that can be treated as filing-complete. Figures for 2025 and 2026 appear lower only because publication typically lags actual filing by around 18 months, not because activity has stopped.
What technology areas dominate transcatheter valve delivery system patents?
A61F, covering implants and prostheses, appears on 57.2% of the 1,851 records, making it the single most common classification. A61B, diagnosis and surgery, is close behind at 43.4%, and A61M, devices for handling body fluids, appears on 23.5%. Because a single record can carry multiple IPC classes, these percentages overlap rather than sum to 100%, and the overlap itself shows how tightly delivery mechanics are claimed alongside the valve implant.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Transcatheter Valve Delivery Systems covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.